Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 19/20 | 0.85 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638492 | 0.92 | PDE10A (1.00) | PDE10APDE3APDE3B | |
| SCHEMBL1636932 | 0.91 | PDE10A (1.00) | PDE10APDE3APDE3B | |
| SCHEMBL1638127 | 0.91 | PDE10A (1.00) | PDE10APDE3A | |
| SCHEMBL1638948 | 0.91 | PDE10A (0.83) | PDE10APDE3APDE3B | |
| SCHEMBL1637122 | 0.91 | PDE10A (0.76) | PDE10APDE3APDE3B | |
| SCHEMBL1636946 | 0.88 | PDE10A (1.00) | PDE10APDE3APDE3B | |
| SCHEMBL28776954 | 0.88 | PDE10A (0.79) | PDE10APDE3APDE3B | |
| SCHEMBL8219672 | 0.86 | PDE10A (0.69) | PDE10APDE3APDE3B | |
| SCHEMBL1638956 | 0.85 | PDE10A (0.83) | PDE10APDE3APDE3B | |
| SCHEMBL4718645 | 0.85 | PDE10A (0.63) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098286-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | claimed |
| EP-2057153-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL- THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H.Lundbeck A/S (DK) | 2009-05-13 | — | — | EP | claimed |
| WO-2008006372-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL- THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H. LUNDBECK A/S (DK) | 2008-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098286-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | PDE5A, PDE2A, PDE3A | PDE10A 7/4885PDE3A 3/4885PDE3B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.